AGBL3 and arthritic joint disease: In a UK cohort enrolling patients with anti-CCP2 and non-specific musculoskeletal symptoms, 30% progressed to clinical arthritis within 3 years, which was predicted by the concurrent presence of RF or anti-CCP3, respectively (104, 105).